Tagged with HE

Indonesia Maura Linda Sitanggang, director general at the Indonesian Ministry of Health, discusses the plans being rolled out to ensure that all Indonesians have access to medicines and how the Indonesian pharmaceutical industry has developed its self-reliance and innovativeness. How does the Ministry of Health organize its priorities and how far…

Austria Harald Isemann, chairman of the Vienna Biocenter (VBC) – one of the leading life science hubs in Europe – and Managing Director of the Institute of Molecular Pathology (IMP), a VBC member, provides insights into the main tasks of the VBC, the organization of the IMP and the challenges it…

Indonesia The Halal Product Assurance Law, enacted in 2014 and due to be implemented across Indonesia in 2019, will mandate that all food and drink that that enters, is distributed, and is traded in Indonesia must be halal certified. However, the law will also extend to cover all medicines, chemicals and…

Algeria Long considered maladies of affluent urban populations in mature Western economies, non communicable diseases (NCDs)– such as diabetes, cancer, chronic respiratory and cardiovascular diseases – have been spreading silently and unchecked throughout the African continent to the point where they are now reaching epidemic proportions and becoming a major determinant…

Indonesia Aylie Widjaja, managing director at Exeltis Indonesia, shares her excitement about developing the company’s footprint in Indonesia, making it a manufacturing hub for Asia, and highlights the challenges in navigating the public market. How do you see the Indonesian healthcare landscape evolving? “We have to give better options to patients…

Pharma PharmaBoardroom’s readers were polled on what they felt was the most disruptive force in the pharmaceutical industry today. Possible answers were big data and digitalization, patient-centricity, economic austerity, and advancements in supply chain management. Big Data and Digitalization Overall, most respondents chose big data and digitalization (34 percent) and economic…

Algeria In June 2017, PharmaBoardroom hosted an exclusive round table discussion with key players in Algerian healthcare on the role of health economics and patient data in health policy decision making. The participants were Dr Djaouad Brahim Bourkaib, Director General of Social Security in the Ministry of Labor, Jean-Paul Digy, Vice President for…

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

Algeria This chart shows how Algeria’s pharmaceuticals and healthcare system has evolved over time; from the creation of the Algerian Central Pharmacy (PCA) back in 1962, all the way to the implementation of the ANPP in 2017. Click here to download the latest roundtable discussion on Algerian healthcare

Algeria Algeria’s key macroeconomic and healthcare indicators. Cardiovascular disease prevalence in North Africa.  Diabetes prevalence in North Africa. The rate of change in the number of years of healthy life lost to obesity in Africa. Click here to download the latest roundtable discussion on Algerian healthcare.

Colombia Rafael Salamanca, the founder of Depósito de Drogas Boyacá, shares his insights on the recent developments of the company in the challenging Colombian logistics environment, while revealing the essence of the company’s success relying on the combination of key factors: product, amount, customer, place and time. You’ve been in the…

Colombia Eduardo Franky Pardo, General Manager of Zambon Colombia, reveals exciting plans on launching the new promising medicine in the recently entered central nervous system therapeutic area, while continuously building their well- reputable presence in Colombia through their philosophy of making quality accessible to everyone. Could you introduce yourself to our…